MedTrace Logo

Vaccination Plus Ontak in Patients With Metastatic Melanoma

NCT00515528 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-01-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune responses. It is also hoped that this will lead to tumor shrinkage.

Conditions

Interventions

BIOLOGICAL

4-peptide melanoma vaccine

Experimental cancer vaccine given as a shot under the skin once every two weeks

DRUG

Ontak

A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Thomas Gajeweski, MD, PhD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-23
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515528 on ClinicalTrials.gov